Cenobamate‐associated weight loss (Cenobaweight study)
A larger than expected number of patients in two centers had significant unintentional weight loss associated with CNB use. In a subset, the effect appeared to be reversible with minor dose reduction, even with severe weight loss. Systematic weight assessment should be considered in all patients on CNB, especially with telehealth. Clinicians should rule out contributing etiologies and consider CNB dose reduction if excessive weight loss occurs.
Authors
- Jong Woo Lee (ORCID: https://orcid.org/0000-0001-5283-7476)
- Gabriel U. Martz (ORCID: https://orcid.org/0000-0002-9675-0265)
- Swetha Ade (ORCID: https://orcid.org/0000-0002-3201-0882)
- Elizabeth A. Thiele (ORCID: https://orcid.org/0000-0003-3431-4713)
- Kang-il Lee
- Jafar Hashem (ORCID: https://orcid.org/0000-0003-3650-6030)
- Shir Ivanier
Institutions
- Brigham and Women's Hospital (US)
- Hartford Hospital (US)
- Novant Health (US)
- Massachusetts General Hospital (US)
- New Hanover Regional Medical Center (US)
- Hartford Financial Services (United States)
Publication Details
- Journal
- Epilepsia
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1111/epi.18481
- Citations
- 2
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 2.33